The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2020
Filed:
Apr. 14, 2017
Applicant:
University of South Florida, Tampa, FL (US);
Inventors:
Jin Q. Cheng, Tampa, FL (US);
Said M. Sebti, Tampa, FL (US);
Assignee:
Other;
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/7064 (2006.01); A61K 31/7076 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/7068 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7064 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/7068 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57426 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/912 (2013.01);
Abstract
This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.